News

The launch follows a CE Mark received late last year.

The objective of this trial was to evaluate safety and tolerability and identify dose level for further evaluation.

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

With this addition, Zeiss completes the Corneal Refractive Workflow, which already includes Visumax 800 and SMILE pro.

Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

The launch follows a CE Mark received in late 2024

The study built on previous research indicating specific retinal variables can serve as disease-related biomarkers in neurodegenerative diseases

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss deep learning systems and whether they can distinguish between optic disc drusen and true papilledema

The Loong Crystal PR IOL is designed for the treatment of myopia in adults ranging from -3.25D to -18.00D.

This phase 2b study (ASPIRE) is currently underway.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

Several pharmaceutical companies have announced new appointments of executives and board members as they prepare for growth in 2025.

Wendy Lee, MD, an oculoplastics specialist and member of the program committee at EnVision Summit, shares an agenda that will include a mix of functional oculoplastics, aesthetics, and live facial rejuvenation demonstrations at the upcoming event, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

The clinical trial successfully met pre-specified visual acuity primary endpoints in both the US and European Union (EU)/United Kingdom (UK) with statistically significant near vision improvements recorded at all time points over 8 hours

The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening

The additions to the ANTERION Cornea App will be commercially available in February 2025

ViGeneron also received approval for dose escalation in the ongoing phase 1b clinical trial.

ViGeneron also received approval for dose escalation in the ongoing phase 1b clinical trial.

The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.

The long-term analysis show clinically and statistically significant reductions in intraocular pressure through up to 36 months postoperatively.

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial